![\"cannconn\"](\"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2025\/06\/headonknees.jpg\")
<\/p>\n<\/p>\n
The conversation around marijuana and mental illness has taken a new, alarming turn. A systematic review published in the journal Biomolecules<\/em> this March presents fresh evidence of a strong link between marijuana use and severe mental health issues, particularly schizophrenia and psychosis. Notably, the study highlights that adolescents are at a significantly higher risk, amplifying urgent questions about its impact on younger users. This article explores the findings and sheds light on how marijuana use could contribute to the development of mental illness.<\/p>\n The Risk of Psychosis and Schizophrenia<\/strong><\/p>\n The Biomolecules<\/em> review analysed data from 10 separate studies, all of which documented an association between marijuana use and an increased risk of developing schizophrenia or psychosis-like events. Crucially, nine of those studies identified the risk as statistically significant. One staggering takeaway from the review is the calculated odds ratio. Individuals using marijuana had a 2.88 higher likelihood of developing psychosis-related conditions than those who abstained.<\/p>\n Adolescents who use marijuana, however, face an even greater threat. The study authors pointed to a \u201clarge age effect,\u201d suggesting that the impact of marijuana on younger users is far more severe. This age factor underscores the vulnerability of developing brains to marijuana-related risks.<\/p>\n Why Adolescents Are at Greater Risk<\/strong><\/p>\n One key hypothesis from the researchers is that marijuana affects adolescents in two major ways. First, it can cause acute psychotic sensations that resemble those triggered by hallucinogenic drugs, indicative of acute toxicity. Second, it disrupts synaptic plasticity during adolescence, leading to developmental changes in the brain that could contribute to long-term mental health issues.<\/p>\n The findings are consistent with a growing body of evidence implicating marijuana use as a driver of severe mental illness. This runs counter to the commonly held notion that mental illnesses like schizophrenia lead people to self-medicate with cannabis. Instead, these results suggest that cannabis use may precede<\/em> such conditions.<\/p>\n The End of the Self-Medication Argument<\/p>\n For years, the \u201cself-medication hypothesis\u201d has been used to explain the relationship between marijuana and schizophrenia. It claimed that individuals with schizophrenia used cannabis as a coping mechanism to manage symptoms. However, the review pushes back strongly against this narrative, stating that in these cases, it\u2019s the cannabis that comes first. Alison Knopf of Alcoholism and Drug Abuse Weekly<\/em> emphasised that these findings mark a key step in resolving the \u201cchicken-and-egg conundrum\u201d around marijuana and mental illness.<\/p>\n Implications for Young People and Beyond<\/strong><\/p>\n The Biomolecules<\/em> review underscores the need for consistent research and public awareness regarding marijuana\u2019s effects on mental health. For teenagers experimenting with cannabis, the data provides a stark warning about the potential consequences on their mental and cognitive futures.<\/p>\n Additionally, it raises important questions for governments, medical professionals, and communities. How can we educate younger generations about these risks to decrease early exposure? And as marijuana is increasingly decriminalised and commercialised worldwide, how do we ensure this knowledge informs broader drug policies?<\/p>\n The new data linking marijuana use with mental illness highlights the importance of informed decision-making, especially for young people and their families. Weed may be legal in many places, but that doesn\u2019t mean it\u2019s harmless. We must look beyond political debates and consider what science tells us about its risks.<\/p>\n